Competitors

Competitors describe Penumbra, Inc.'s market in their own filings and calls. These verified passages and visual pages show where their strategies meet, using source documents preserved in Sources.

Boston Scientific Corporation (BSX)

The most consequential name in the set: on January 15, 2026 Boston Scientific agreed to acquire Penumbra outright for roughly $14.5 billion. BSX already fields overlapping venous/pulmonary thrombectomy tools (AngioJet, EKOS) inside its Peripheral Interventions business, and its own filings and calls describe Penumbra's business, portfolio and the strategic logic of the deal in detail — a competitor turned acquirer.

Boston Scientific's 10-K formally discloses the agreement to acquire Penumbra — describing the subject's business (thrombectomy for peripheral vascular clot removal), naming its Lightning Bolt and Lightning Flash CAVT systems, and putting the price at $374 per share / ~$14.5 billion.

On January 15, 2026, we announced our entry into a definitive agreement to acquire 100 percent of Penumbra, Inc. (Penumbra), a publicly traded medical technology company primarily focused on innovative medical thrombectomy products for use in peripheral vascular procedures in the removal of blood clots and blockages. The Penumbra portfolio includes the Lightning Bolt™ and Lightning Flash™ Computer Assisted Vacuum Thrombectomy (CAVT™) Systems. The purchase price is valued at $374 per share, or approximately $14.500 billion. The transaction is expected to close during 2026, subject to customary closing conditions.

p. 9 · Read in context →

On the Q4 2025 call, a Boston Scientific executive frames the strategic rationale — the Penumbra deal as an entry into the 'high-growth' pulmonary embolism and neurovascular markets, layered onto BSX's existing scaled vascular sales force.

The announcement of Penumbra, as we talked about, is really exciting for us. It gets us into new high-growth markets in PE and neurovascular, just to name a few, with a highly scaled sales force. So in terms of commercial clinical capability, I think we're pretty unmatched in that area.

p. 9 · Read in context →

Q1 2026 deal-timing update: BSX expects the Penumbra acquisition to close in the second half of 2026, pending Penumbra's May 6 shareholder vote and remaining regulatory clearances.

We remain excited about the opportunity to combine the Penumbra team and their highly differentiated portfolio with Boston Scientific. We anticipate that the deal will close in the second half of '26, subject to the Penumbra shareholder vote on May 6 and the receipt of the remaining regulatory clearances.

p. 3 · Read in context →

Medtronic plc (MDT)

Medtronic's Neurovascular operating unit is the classic head-to-head competitor in acute ischemic and hemorrhagic stroke — the exact clinical space of Penumbra's aspiration-thrombectomy franchise — with a coils, neurovascular-stent and flow-diversion portfolio sitting inside a ~$10 billion Neuroscience segment.

Medtronic's FY2026 10-K places Neurovascular as a distinct operating unit whose products treat 'acute ischemic and hemorrhagic stroke' — the same indication Penumbra's neuro thrombectomy business targets.

Our Specialty Therapies division includes the following Operating Units: Neurovascular; Ear, Nose, and Throat (ENT); and Pelvic Health. The division develops, manufactures, and markets products and therapies to treat patients afflicted with acute ischemic and hemorrhagic stroke, ENT diseases, and patients suffering from overactive bladder, and (non-obstructive) urinary retention.

p. 11 · Read in context →

Medtronic's neurovascular product line — coils, neurovascular stents and flow-diversion devices for the brain vasculature — disclosed within a Neuroscience segment reporting $10.3 billion of FY2026 net sales.

Neuroscience's products also focus on therapies to treat the diseases of the vasculature in and around the brain, including coils, neurovascular stents, and flow diversion products, as well as products to treat the ear, nose, and throat (ENT), and the treatment of overactive bladder and urinary retention. […] Neuroscience’s net sales for fiscal year 2026 were $10.3 billion, an increase of 4 percent as compared to fiscal year 2025

p. 68 · Read in context →

Stryker Corporation (SYK)

Stryker names Penumbra directly as one of five leading global competitors in its Vascular / Neuro Cranial business, which sells minimally invasive devices for acute ischemic and hemorrhagic stroke and venous thromboembolism — and on its earnings call claims to be the largest neurovascular player in the market.

Stryker's FY2025 10-K lists Penumbra by name as one of the five leading global competitors in its Vascular and Neuro Cranial business, alongside Medtronic, J&J MedTech and Terumo.

We are one of five leading global competitors in Vascular and Neuro Cranial; the other four being Medtronic, Johnson & Johnson MedTech, Terumo Corporation and Penumbra, Inc.

p. 3 · Read in context →

On the Q4 2025 call, Stryker management claims market leadership in neurovascular — the category where Penumbra competes — stating it became the largest player roughly a year earlier.

But our hemorrhagic business continues to be very strong, and we are now the largest neurovascular player in the marketplace. We took over leadership roughly about a year ago and have continued to be the largest player.

p. 5 · Read in context →

Johnson & Johnson (JNJ)

Through its MedTech Cardiovascular portfolio, J&J offers neurovascular care that treats stroke via minimally invasive, catheter-based approaches used by neurointerventional specialists — the same call point and procedure Penumbra sells into.

J&J's FY2025 10-K situates its neurovascular stroke-care business within MedTech Cardiovascular, delivered through the same minimally invasive catheter-based approach and to the same neurointerventional specialists that Penumbra targets.

circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD), and neurovascular care that treats stroke and other conditions. These offerings are primarily delivered through minimally invasive, catheter based approaches and are used by interventional cardiologists, electrophysiologists and neurointerventional specialists.

p. 10 · Read in context →

AngioDynamics, Inc. (ANGO)

AngioDynamics competes squarely with Penumbra's peripheral mechanical-thrombectomy franchise through its AlphaVac / AngioVac thrombus-management portfolio, and names Penumbra directly in both its 10-K competition section and its management's discussion of the thrombectomy landscape.

AngioDynamics' competition section names Penumbra among its primary competitors, alongside Boston Scientific, Medtronic, Stryker and other large device makers.

We encounter significant competition across our product lines and in each market in which our products are sold. […] Our primary competitors include: Boston Scientific Corporation; Cook Medical; Medical Components, Inc. (MedComp); TeleFlex Medical; Becton Dickinson; Medtronic; Merit Medical; Terumo Medical Corporation; Johnson and Johnson; Philips Healthcare; Stryker Corporation; Penumbra, Inc.; Varian Medical Systems; Abbott Laboratories and Total Vein Systems.

p. 15 · Read in context →

AngioDynamics' Thrombus Management portfolio — the AlphaVac Mechanical Thrombectomy System and AngioVac — addresses the same venous/peripheral clot-removal use case as Penumbra's CAVT devices.

Our Thrombus Management portfolio includes the AlphaVac Mechanical Thrombectomy System, AngioVac venous drainage cannula and circuit, as well as catheter directed thrombolytic devices, including the Uni-Fuse system and the Uni-Fuse+ system. AngioDynamics offers a range of options when treating thrombus and removing fresh, soft thrombi or emboli.

p. 7 · Read in context →

On the Q4 FY2026 call, AngioDynamics' CEO characterizes the thrombectomy field — grouping Boston Scientific/Penumbra and Inari/Stryker as the go-to-market forces its own products compete against.

You now have Boston and Penumbra going to market differently than it was in the past. You've got Inari and Stryker going to market differently. Our product competes really well with both of those. Those are great products and great companies behind them, but our product is really good.

p. 8 · Read in context →